Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
暂无分享,去创建一个
[1] H. Lynch,et al. Addressing Financial Barriers to Enrollment in Clinical Trials. , 2018, JAMA oncology.
[2] P. Rabins,et al. Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role , 2018, Dementia.
[3] I. Cohen,et al. A Framework for Ethical Payment to Research Participants , 2018, The New England journal of medicine.
[4] H. Lynch,et al. Paying Research Participants: The Outsized Influence of "Undue Influence". , 2017, IRB.
[5] Jared A. Rowland,et al. Neuropsychological Test Administration by Videoconference: A Systematic Review and Meta-Analysis , 2017, Neuropsychology Review.
[6] J. Karlawish,et al. Unfinished Business in Preventing Alzheimer Disease. , 2016, JAMA internal medicine.
[7] M. Weiner,et al. The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions , 2016, Alzheimer's & Dementia.
[8] E. Teng,et al. African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials , 2016, Alzheimer's & dementia.
[9] Roy W Jones,et al. Drug development in Alzheimer’s disease: the path to 2025 , 2016, Alzheimer's Research & Therapy.
[10] R. Banzi,et al. Older patients are still under-represented in clinical trials of Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.
[11] R. Banzi,et al. Older patients are still under-represented in clinical trials of Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.
[12] P. Doraiswamy,et al. Underrepresentation of African-Americans in Alzheimer's Trials: A Call for Affirmative Action , 2016, Front. Aging Neurosci..
[13] Hang Lee,et al. Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. , 2016, The oncologist.
[14] Alzheimer’s Association,et al. 2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.
[15] M. Prince,et al. World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .
[16] J. Karlawish,et al. Frequency and Impact of Informant Replacement in Alzheimer Disease Research , 2015, Alzheimer disease and associated disorders.
[17] David S. Miller,et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials , 2015, Alzheimer's Research & Therapy.
[18] Sirpa Hartikainen,et al. Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors , 2015, PloS one.
[19] Sasha Colby,et al. Projections of the Size and Composition of the U.S. Population: 2014 to 2060. Population Estimates and Projections. Current Population Reports. P25-1143. , 2015 .
[20] J. Karlawish,et al. Why are Spousal Caregivers More Prevalent than Nonspousal Caregivers as Study Partners in AD Dementia Clinical Trials? , 2015, Alzheimer disease and associated disorders.
[21] P. Rabins,et al. Researchers’ perspectives on the role of study partners in dementia research , 2014, International Psychogeriatrics.
[22] Laurie M. Ryan,et al. Obstacles and opportunities in Alzheimer's clinical trial recruitment. , 2014, Health affairs.
[23] Travis J. Beaulieu,et al. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development , 2014, Annals of the New York Academy of Sciences.
[24] J. Kimmelman,et al. The questionable use of unequal allocation in confirmatory trials , 2014, Neurology.
[25] Paco Martorell,et al. Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.
[26] J. Karlawish,et al. Effect of study partner on the conduct of Alzheimer disease clinical trials , 2013, Neurology.
[27] Dongwen Wang,et al. Willingness of Parkinson's disease patients to participate in research using internet-based technology. , 2012, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[28] R. Little,et al. The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.
[29] J. Karlawish,et al. Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer’s Disease Clinical Trials , 2012, Dementia and Geriatric Cognitive Disorders.
[30] L. Fogarty,et al. Decision making for participation in dementia research. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[31] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[32] J. Karlawish,et al. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials , 2010, Alzheimer's Research & Therapy.
[33] M. Sano,et al. The net effect of alternative allocation ratios on recruitment time and trial cost , 2009, Clinical trials.
[34] J. Karlawish,et al. How redesigning AD clinical trials might increase study partners’ willingness to participate , 2008, Neurology.
[35] A. Zaslavsky,et al. Randomized Trial of $20 Versus $50 Incentives to Increase Physician Survey Response Rates , 2008, Medical care.
[36] A. Stewart,et al. RACE/ETHNIC DIFFERENCES IN AD SURVIVAL IN US ALZHEIMER'S DISEASE CENTERS , 2008, Neurology.
[37] J. Varni,et al. Costs of recruiting couples to a clinical trial. , 2007, Contemporary clinical trials.
[38] E. Emanuel,et al. Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? , 2005, PLoS medicine.
[39] J. Grace,et al. Validity of Informant Reports About AD and MCI Patients’ Memory , 2004, Alzheimer disease and associated disorders.
[40] K. Maschke,et al. National practices regarding payment to research subjects for participating in pediatric research. , 2002, Pediatrics.
[41] C. Grady,et al. The ethics of paying for children's participation in research. , 2002, The Journal of pediatrics.
[42] J. Karlawish,et al. The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.
[43] J. Karlawish,et al. How do AD patients and their caregivers decide whether to enroll in a clinical trial? , 2001, Neurology.
[44] B. Tarlow,et al. The Cost of Recruiting Alzheimer’s Disease Caregivers for Research , 2000, Journal of aging and health.
[45] T. Treves,et al. Demented patients' participation in a clinical trial: factors affecting the caregivers' decision , 2000, International journal of geriatric psychiatry.
[46] C. Grady,et al. What's the price of a research subject? Approaches to payment for research participation. , 1999, The New England journal of medicine.
[47] D. Knopman,et al. The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.
[48] D. Gillen,et al. Constructing a Local Potential Participant Registry to Improve Alzheimer's Disease Clinical Research Recruitment. , 2018, Journal of Alzheimer's disease : JAD.
[49] E. Largent,et al. Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward. , 2018, Yale journal of health policy, law, and ethics.
[50] C. Jack,et al. Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .
[51] C. V. Van Houtven,et al. The effect of informal care on work and wages. , 2013, Journal of health economics.